Cost-effectiveness and potential value of pharmaceutical treatment of nonalcoholic fatty liver disease

References

• Rinella ME. Nonalcoholic fatty liver disease: a systematic review. Jama. 2015;313(22):2263–2273.
   PubMed Web of Science ®Google Scholar
• Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328–357.
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Tampi R, Priyadarshini M, et al. Burden of illness and economic model for patients with nonalcoholic steatohepatitis in the United States. Hepatology. 2019;69(2):564–572.
   PubMed Web of Science ®Google Scholar
• Estes C, Razavi H, Loomba R, et al. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018;67(1):123–133.
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Blissett D, Blissett R, et al. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology. 2016;64(5):1577–1586.
   PubMed Web of Science ®Google Scholar
• Hirode G, Vittinghoff E, Wong RJ. Increasing clinical and economic burden of nonalcoholic fatty liver disease among hospitalized adults in the United States. J Clin Gastroenterol. 2019;53(10):765–771.
   PubMed Web of Science ®Google Scholar
• Allen AM, Van Houten HK, Sangaralingham LR, et al. Healthcare cost and utilization in nonalcoholic fatty liver disease: real-world data from a large U.S. Claims database. Hepatology. 2018;68(6):2230–2238.
   PubMed Web of Science ®Google Scholar
• Musso G, Cassader M, Rosina F, et al. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in nonalcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia. 2012;55(4):885–904.
   PubMed Web of Science ®Google Scholar
• Caro JJ, Briggs AH, Siebert U, et al. Modeling good research practices-overview: a report of the ISPOR-SMDM modeling good research practices task force-1. Value Health. 2012;15(6):796–803.
   PubMed Web of Science ®Google Scholar
• Husereau D, Drummond M, Petrou S, et al. Consolidated health economic evaluation reporting standards (CHEERS) statement. Value Health. 2013;16(2):e1–e5.
   PubMed Web of Science ®Google Scholar
• Hagstrom H, Nasr P, Ekstedt M, et al. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. J Hepatol. 2017;67(6):1265–1273.
   PubMed Web of Science ®Google Scholar
• Pearson S, Banken R, Chapman R, et al. Obeticholic Acid for the Treatment of Nonalcoholic Steatohepatitis: Comparative Clinical Effectiveness and Value: final report: The Institute for Clinical and Economic Review (ICER). 2016.
   Google Scholar
• Chongmelaxme B, Phisalprapa P, Sawangjit R, et al. Weight reduction and pioglitazone are cost-effective for the treatment of non-alcoholic fatty liver disease in Thailand. Pharmacoeconomics. 2019;37(2):267–278.
   PubMed Web of Science ®Google Scholar
• Klebanoff MJ, Corey KE, Chhatwal J, et al. Bariatric surgery for nonalcoholic steatohepatitis: a clinical and cost-effectiveness analysis. Hepatology. 2017;65(4):1156–1164.
   PubMed Web of Science ®Google Scholar
• Weinstein MC, Siegel JE, Gold MR, et al. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA. 1996;276(15):1253–1258.
   PubMed Web of Science ®Google Scholar
• Ascha MS, Hanouneh IA, Lopez R, et al. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology. 2010;51(6):1972–1978.
   PubMed Web of Science ®Google Scholar
• US Centers for Disease Control and Prevention National Center for Health Statistics. The Linkage of National Center for Health Statistics Survey Data to the National Death Index – 2015 Linked Mortality File (LMF): Methodology Overview and Analytic Considerations 2018. [cited January 2, 2020]. Available from: https://www.cdc.gov/nchs/data-linkage/mortality-methods.htm.
   Google Scholar
• Davis KL, Mitra D, Medjedovic J, et al. Direct economic burden of chronic hepatitis C virus in a United States managed care population. J Clin Gastroenterol. 2011;45(2):e17-24–e24.
   PubMed Web of Science ®Google Scholar
• Dulai PS, Singh S, Patel J, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis. Hepatology. 2017;65(5):1557–1565.
   PubMed Web of Science ®Google Scholar
• Hui JM, Kench JG, Chitturi S, et al. Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. Hepatology. 2003;38(2):420–427.
   PubMed Web of Science ®Google Scholar
• Jain A, Reyes J, Kashyap R, et al. Long-term survival after liver transplantation in 4,000 consecutive patients at a single center. Ann Surg. 2000;232(4):490–500.
   PubMed Web of Science ®Google Scholar
• National Institutes of Health Surveillance, Epidemiology, and End Results Program. Liver and Intrahepatic Bile Duct Cancer Recent Trends in SEER Age-Adjusted Incidence Rates, 2000–2016. 2020. [cited April 6, 2020]. Available from: https://seer.cancer.gov/explorer/application.html?site=35&data_type=1&graph_type=2&compareBy=sex&chk_sex_1=1&race=1&age_range=1&stage=101&rate_type=2&advopt_precision=1&advopt_display=2.
   Google Scholar
• Ratziu V, Bonyhay L, Di Martino V, et al. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology. 2002;35(6):1485–1493.
   PubMed Web of Science ®Google Scholar
• Saab S, Hunt DR, Stone MA, et al. Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model. Liver Transpl. 2010;16(6):748–759.
   PubMed Web of Science ®Google Scholar
• Sanyal AJ, Banas C, Sargeant C, et al. Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology. 2006;43(4):682–689.
   PubMed Web of Science ®Google Scholar
• Thuluvath PJ, Guidinger MK, Fung JJ, et al. Liver transplantation in the United States, 1999-2008. Am J Transplant. 2010;10(4 Pt 2):1003–1019.
   PubMed Web of Science ®Google Scholar
• Wolfe RA, Roys EC, Merion RM. Trends in organ donation and transplantation in the United States, 1999-2008. Am J Transplant. 2010;10(4 Pt 2):961–972.
   PubMed Web of Science ®Google Scholar
• Wong RJ, Aguilar M, Cheung R, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology. 2015;148(3):547–555.
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73–84.
   PubMed Web of Science ®Google Scholar
• Unalp-Arida A, Ruhl CE. Noninvasive fatty liver markers predict liver disease mortality in the US population. Hepatology. 2016;63(4):1170–1183.
   PubMed Web of Science ®Google Scholar
• Arias E. United States life tables, 2017. Natl Vital Stat Rep. 2019;68(7):1–66.
   PubMedGoogle Scholar
• Habka D, Mann D, Landes R, et al. Future economics of liver transplantation: a 20-year cost modeling forecast and the prospect of bioengineering autologous liver grafts. PLOS One. 2015;10(7):e0131764.
   PubMed Web of Science ®Google Scholar
• Rustgi VL, John T, Catalano C, et al. Health care resource use and cost burden of chronic kidney disease in patients with chronic liver disease: a real-world claims analysis. Hepatol Commun. 2020;4(10):1404–1418.
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Tampi RP, Racila A, et al. Economic and clinical burden of nonalcoholic steatohepatitis in patients with type 2 diabetes in the US. Diabetes Care. 2020;43(2):283–289.
   PubMed Web of Science ®Google Scholar
• Brunt EM, Kleiner DE, Wilson LA, et al. Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology. 2011;53(3):810–820.
   PubMed Web of Science ®Google Scholar
• Poynard T, Imbert-Bismut F, Munteanu M, et al. Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp Hepatol. 2004;3(1):8.
   PubMedGoogle Scholar
• US Bureau of Labor Statistics. Consumer price index for medical care in the US city average, all urban consumers, seasonally adjusted 2020. [cited April 6, 2020]. Available from: https://www.bls.gov/cpi/data.htm.).
   Google Scholar
• David K, Kowdley KV, Unalp A, et al. Quality of life in adults with nonalcoholic fatty liver disease: baseline data from the nonalcoholic steatohepatitis clinical research network. Hepatology. 2009;49(6):1904–1912.
   PubMed Web of Science ®Google Scholar
• Nichol MB, Sengupta N, Globe DR. Evaluating quality-adjusted life years: estimation of the health utility index (HUI2) from the SF-36. Med Decis Making. 2001;21(2):105–112.
   PubMed Web of Science ®Google Scholar
• Chong CA, Gulamhussein A, Heathcote EJ, et al. Health-state utilities and quality of life in hepatitis C patients. Am J Gastroenterology. 2003;98(3):630–638.
   PubMed Web of Science ®Google Scholar
• Aberg F, Maklin S, Rasanen P, et al. Cost of a quality-adjusted life year in liver transplantation: the influence of the indication and the model for end-stage liver disease score. Liver Transpl. 2011;17(11):1333–1343.
   PubMed Web of Science ®Google Scholar
• Hanmer J, Lawrence WF, Anderson JP, et al. Report of nationally representative values for the noninstitutionalized US adult population for 7 health-related quality-of-life scores. Med Decis Making. 2006;26(4):391–400.
   PubMed Web of Science ®Google Scholar
• Rind DM, Hansen R, Guzauskas G, et al. Obeticholic Acid for the Treatment of Nonalcoholic Steatohepatitis with Fibrosis: Effectiveness and Value: The Institute for Clinical and Economic Review (ICER); 2020.
   Google Scholar
• Thompson Reuters. Red book 2020: pharmacy's fundamental reference. Montvale (NJ): PDR Network LLC; 2020.
   Google Scholar
• Eddy DM, Hollingworth W, Caro JJ, et al. Model transparency and validation: a report of the ISPOR-SMDM modeling good research practices task Force-7. Value Health. 2012;15(6):843–850.
   PubMed Web of Science ®Google Scholar
• Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness-the curious resilience of the $50,000-per-QALY threshold. N Engl J Med. 2014;371(9):796–797.
   PubMed Web of Science ®Google Scholar
• Romero-Gomez M, Zelber-Sagi S, Trenell M. Treatment of NAFLD with diet, physical activity and exercise. J Hepatol. 2017;67(4):829–846.
   PubMed Web of Science ®Google Scholar
• Moroshko I, Brennan L, O'Brien P. Predictors of dropout in weight loss interventions: a systematic review of the literature. Obes Rev. 2011;12(11):912–934.
   PubMed Web of Science ®Google Scholar
• Jacobs-van der Bruggen MA, van Baal PH, Hoogenveen RT, et al. Cost-effectiveness of lifestyle modification in diabetic patients. Diabetes Care. 2009;32(8):1453–1458.
   PubMed Web of Science ®Google Scholar
• Fakhry TK, Mhaskar R, Schwitalla T, et al. Bariatric surgery improves nonalcoholic fatty liver disease: a contemporary systematic review and meta-analysis. Surg Obes Relat Dis. 2019;15(3):502–511.
   PubMed Web of Science ®Google Scholar
• Ekstedt M, Hagstrom H, Nasr P, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2015;61(5):1547–1554.
   PubMed Web of Science ®Google Scholar
• Rushing J, Wing R, Wadden TA, et al. Cost of intervention delivery in a lifestyle weight loss trial in type 2 diabetes: results from the look AHEAD clinical trial. Obes Sci Pract. 2017;3(1):15–24.
   PubMed Web of Science ®Google Scholar